Press Releases

The latest news about PosiRx


CHICAGO, IL – September 26, 2013 (PRNewswire) – Positron Corporation (OTCBB:POSC) is pleased to announce it has entered into a licensing agreement with the Institute for Nuclear Research of the Russian Academy of Science (INR), Moscow, Russia, for its know-how, inventions and technology related to the production of... Read More


CHICAGO, IL – September 23, 2013 (PRNewswire) – Positron Corporation (OTCBB:POSC),(the “Company”) a nuclear medicine healthcare company specializing in the business of cardiac PET, announced today that it had filed a Preliminary Information Statement with the Securities and Exchange Commission (“SEC”) to effect a... Read More


CHICAGO, IL – July 29, 2013 (PRNewswire) – Positron Corporation (OTCBB:POSC) announces it has entered into a multi-year radioisotope supply agreement with iThemba LABS of Cape Town, South Africa.  The supply agreement contracts the procurement of raw material, strontium-82 (Sr-82), from iThemba LABS for further... Read More


CHICAGO, IL – May 3, 2013 (PRNewswire) – Positron Corporation (OTCBB: POSC), a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging and high tech pharmacy automation, today announced a co-marketing agreement with Biologics Modular.  Biologics Modular... Read More


CHICAGO, IL – May 1, 2013 (PRNewswire) – Positron Corporation (OTCBB: POSC) is pleased to announce the release of the PosiRx® 3000-Series, its latest pharmacy automation systems. The PosiRx® 3000-Series are the first systems to automate and encompass the complete compounding process, from generator elution to dose... Read More


Positron Announces Strontium Sale

Chicago, IL – December 7, 2012 (PRNewswire) – Positron Corporation (OTCBB:POSC) posts their first commercial sale and shipment of Active Pharmaceutical Ingredient (API) grade Strontium-82 to a North American pharmaceutical company. Manhattan Isotope Technology (MIT), LLC, a wholly owned subsidiary of Position... Read More